Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Pfizer And Mannkind Reach Insulin Deal
September 22, 2008
| A version of this story appeared in
Volume 86, Issue 38
Pfizer and MannKind have reached an agreement under which patients of Pfizer's Exubera inhaled insulin who need an inhaled product will transition to MannKind's Technosphere insulin, which recently completed Phase III clinical trials. Pfizer invested billions of dollars developing inhaled insulin, but the drug never caught on with patients and Pfizer eventually withdrew it from the market (C&EN, May 12, page 24). MannKind, which is the last company to pursue the market, recently opened a $200 million plant in Danbury, Conn., to manufacture its product, once approved.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter